Monthly sulfadoxine/pyrimethamine-amodiaquine or dihydroartemisinin-piperaquine as malaria chemoprevention in young Kenyan children with sickle cell anemia: A randomized controlled trial
Fig 2
Main hematologic outcomes in the AT population according to subgroup.
Points are estimates of the IRR relative to daily Proguanil. Bars are 95% CI. AT, As-Treated; CI, confidence interval; DP, dihydroartemisinin-piperaquine; g/dL, grams per deciliter; IRR, incidence rate ratio; SP-AQ, sulfadoxine/pyrimethamine-amodiaquine.